Triterpenoid 2-deoxy glycosides of general formula I wherein: "a" is a single bond (s), "b" is a double bond (d); R 2 is selected from the group comprising COOH, COOCH 2 C 6 H 5, COO(CH 2) n CH 3, wherein n = 0-10, and CH 2 OR 2a; R 3 is CH 3 or CHO; R 4 is CH 3; X 1 is CHOR 1 or C=O; X 2 is C=O; X 3 is CH 2 or C=O; R 1 is selected from the group comprising acetyl, 2-deoxy-α-D-galactopyranosyl, 3,4,6-tri- O -acetyl-2-deoxy-α-D-galactopyranosyl, 2-deoxy-α-D-glucopyranosyl, 3,4,6-tri- O- acetyl-2-deoxy-α-D-glucopyranosyl, 4,6-di- O -acetyl-3-brom-2,3-dideoxy-α-D-glucopyranosyl, 4-(2',3',4',6'-tetra- O -acetyl-β-D-galactopyranosyl)-3,6-di- O -acetyl-2-deoxy-α-D-glucopyranosyl, 4-(β-D-galactopyranosyl)-2-deoxy-α-D-glucopyranosyl, 4-(2',3',4',6'-tetra- O -acetyl-α-D-glucopyranosyl)-3,6-di- O -acetyl-2-deoxy-α-D-glucopyranosyl, 4-(α-D-glucopyranosyl)-2-deoxy-α-D-glucopyranosyl, 4-(2',3',4',6'-tetra- O -acetyl-β-D-galactopyranosyl)-6- O -acetyl-2,3-dideoxy-α-D- erythro -hex-2-enopyranosyl, 4-(β-D-galactopyranosyl)-2,3-dideoxy-α-D- erythro -hex-2-enopyranosyl, 4-(2',3',4',6'-tetra- O -acetyl-α-D-glucopyranosyl)-6- O -acetyl-2,3-dideoxy-α-D- erythro -hex-2-enopyranosyl, 4-(α-D-glucopyranosyl)-2,3-dideoxy-α-D- erythro -hex-2-enopyranosyl, 3,4-di- O -acetyl-2-deoxy-α-L-rbamnosyl, 2-deoxy-α-L-rhamnosyl, 4- O -acetyl-2,3-dideoxy-3-brom-α-L-rhamnosyl, 4-O-acetyl-2,3,6-trideoxy-α-L- erythro -hex-2-enopyranosyl, 2,3,6-trideoxy-α-L- erythro -hex-2-enopyranosyl and hydrogen; R 2a is selected from the group comprising 2-deoxy-α-D-galactopyranosyl, 3,4,6-tri- O- acetyl-2-deoxy-α-D-galactopyranosyl, 2-deoxy-α-D-glucopyranosyl, 3,4,6-tri- O- acetyl-2-deoxy-α-D-glucopyranosyl, 4,6-di- O -acetyl-3-brom-2,3-dideoxy-α-D-glucopyranosyl, 4-(2',3',4',6'-tetra- O -acetyl-β-D-galactopyranosyl)-3,6-di- O -acetyl-2-deoxy-α-D-glucopyranosyl, 4-(β-D-galactopyranosyl)-2-deoxy-α-D-glucopyranosyl, 4-(2',3',4',6'-tetra- O -acetyl-α-D-glucopyranosyl)-3,6-di- O -acetyl-2-deoxy-α-D-glucopyranosyl, 4-(α-D-glucopyranosyl)-2-deoxy-α-D-glucopyranosyl, 4-(2',3',4',6'-tetra- O -acetyl-β-D-galactopyranosyl)-6- O -acetyl-2,3-dideoxy-α-D- erythro -hex-2-enopyranosyl, 4-(β-D-galactopyranosyl)-2,3-dideoxy-α-D- erythro -hex-2-enopyranosyl, 4-(2',3',4',6'-tetra- O -acetyl-α-D-glucopyranosyl)-6- O -acetyl-2,3-dideoxy-α-D- erythro -hex-2-enopyranosyl, 4-(α-D-glucopyranosyl)-2,3-dideoxy-α-D- erythro -hex-2-enopyranosyl, 3,4-di- O -acetyl-2-deoxy-α-L-rbamnosyl, 2-deoxy-α-L-rhamnosyl, 4- O -acetyl-2,3-dideoxy-3-brom-α-L-rhamnosyl, 4-O-acetyl-2,3,6-trideoxy-α-L- erythro -hex-2-enopyranosyl, 2,3,6-trideoxy-α-L- erythro -hex-2-enopyranosyl and hydrogen; provided that: - at least one of X 1 and R 2 comprises 2-deoxy glycosyl for use in the treatment of tumor diseases and diseases with pathological proliferation. "a" is a single bond (s), "b" is a double bond (d); R 2 is selected from the group comprising COOH, COOCH 2 C 6 H 5, COO(CH 2) n CH 3, wherein n = 0-10, and CH 2 OR 2a; R 3 is CH 3 or CHO; R 4 is CH 3; X 1 is CHOR 1 or C=O; X 2 is C=O; X 3 is CH 2 or C=O; R 1 is selected from the group comprising acetyl, 2-deoxy-α-D-galactopyranosyl, 3,4,6-tri- O -acetyl-2-deoxy-α-D-galactopyranosyl, 2-deoxy-α-D-glucopyranosyl, 3,4,6-tri- O- acetyl-2-deoxy-α-D-glucopyranosyl, 4,6-di- O -acetyl-3-brom-2,3-dideoxy-α-D-glucopyranosyl, 4-(2',3',4',6'-tetra- O -acetyl-β-D-galactopyranosyl)-3,6-di- O -acetyl-2-deoxy-α-D-glucopyranosyl, 4-(β-D-galactopyranosyl)-2-deoxy-α-D-glucopyranosyl, 4-(2',3',4',6'-tetra- O -acetyl-α-D-glucopyranosyl)-3,6-di- O -acetyl-2-deoxy-α-D-glucopyranosyl, 4-(α-D-glucopyranosyl)-2-deoxy-α-D-glucopyranosyl, 4-(2',3',4',6'-tetra- O -acetyl-β-D-galactopyranosyl)-6- O -acetyl-2,3-dideoxy-α-D- erythro -hex-2-enopyranosyl, 4-(β-D-galactopyranosyl)-2,3-dideoxy-α-D- erythro -hex-2-enopyranosyl, 4-(2',3',4',6'-tetra- O -acetyl-α-D-glucopyranosyl)-6- O -acetyl-2,3-dideoxy-α-D- erythro -hex-2-enopyranosyl, 4-(α-D-glucopyranosyl)-2,3-dideoxy-α-D- erythro -hex-2-enopyranosyl, 3,4-di- O -acetyl-2-deoxy-α-L-rbamnosyl, 2-deoxy-α-L-rhamnosyl, 4- O -acetyl-2,3-dideoxy-3-brom-α-L-rhamnosyl, 4-O-acetyl-2,3,6-trideoxy-α-L- erythro -hex-2-enopyranosyl, 2,3,6-trideoxy-α-L- erythro -hex-2-enopyranosyl and hydrogen; R 2a is selected from the group comprising 2-deoxy-α-D-galactopyranosyl, 3,4,6-tri- O- acetyl-2-deoxy-α-D-galactopyranosyl, 2-deoxy-α-D-glucopyranosyl, 3,4,6-tri- O- acetyl-2-deoxy-α-D-glucopyranosyl, 4,6-di- O -acetyl-3-brom-2,3-dideoxy-α-D-glucopyranosyl, 4-(2',3',4',6'-tetra- O -acetyl-β-D-galactopyranosyl)-3,6-di- O -acetyl-2-deoxy-α-D-glucopyranosyl, 4-(β-D-galactopyranosyl)-2-deoxy-α-D-glucopyranosyl, 4-(2',3',4',6'-tetra- O -acetyl-α-D-glucopyranosyl)-3,6-di- O -acetyl-2-deoxy-α-D-glucopyranosyl, 4-(α-D-glucopyranosyl)-2-deoxy-α-D-glucopyranosyl, 4-(2',3',4',6'-tetra- O -acetyl-β-D-galactopyranosyl)-6- O -acetyl-2,3-dideoxy-α-D- erythro -hex-2-enopyranosyl, 4-(β-D-galactopyranosyl)-2,3-dideoxy-α-D- erythro -hex-2-enopyranosyl, 4-(2',3',4',6'-tetra- O -acetyl-α-D-glucopyranosyl)-6- O -acetyl-2,3-dideoxy-α-D- erythro -hex-2-enopyranosyl, 4-(α-D-glucopyranosyl)-2,3-dideoxy-α-D- erythro -hex-2-enopyranosyl, 3,4-di- O -acetyl-2-deoxy-α-L-rbamnosyl, 2-deoxy-α-L-rhamnosyl, 4- O -acetyl-2,3-dideoxy-3-brom-α-L-rhamnosyl, 4-O-acetyl-2,3,6-trideoxy-α-L- erythro -hex-2-enopyranosyl, 2,3,6-trideoxy-α-L- erythro -hex-2-enopyranosyl and hydrogen; provided that: - at least one of X 1 and R 2 comprises 2-deoxy glycosyl for use in the treatment of tumor diseases and diseases with pathological proliferation. - at least one of X 1 and R 2 comprises 2-deoxy glycosyl for use in the treatment of tumor diseases and diseases with pathological proliferation.